- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Suneva acquires Spear product line
Suneva Medical has acquired a new product line, including worldwide rights to Refissa (tretinoin 0.05 percent), from Spear Pharmaceuticals.
San Diego - Suneva Medical, an aesthetics company based here, has acquired a new product line, including worldwide rights to Refissa (tretinoin 0.05 percent), from Spear Pharmaceuticals.
The acquisition is expected to be a significant source of revenue growth, the San DiegoBusiness Journal reports. Suneva’s dermatological product line already includes dermal filler Artefill (polymethylmethacrylate), and ReGenica, an anti-aging cream. Suneva also signed licensing agreements with Histogen for aesthetic skincare products earlier this year.
The Business Journal quotes Suneva CEO Nicholas Teti as saying, “It’s an excellent package of products to bring in right now.”
Suneva is expected to add new positions in marketing and sales.
Go back to the Dermatology Times eNews newsletter.
